PMC7451149_01
Magnetic resonance imaging brain (a) sagittal, (b) coronal demonstrating a sellar lesion with suprasellar extension exhibiting homogenous enhancement. Red arrows demonstrate a sellar lesion with suprasellar extension with homogenous enhancement.
SNI-11-238-g001.jpg
PMC7451149_01_SNI-11-238-g001.jpg
F1
As demonstrated in [Figure 1], it revealed a sellar lesion with suprasellar extension exhibiting homogenous enhancement.
On 3-month follow-up, magnetic resonance imaging (a) sagittal and (b) coronal sequences demonstrated progressive and enlarging lesion. Red arrows demonstrate the progressively enlarging lesion.
SNI-11-238-g002.jpg
PMC7451149_01_SNI-11-238-g002.jpg
F2
On 3-month follow-up, imaging demonstrated progressive and enlarging lesion, as demonstrated in [Figure 2].
Magnetic resonance imaging brain imaging (a) sagittal and (b) postoperative imaging, as visualized in demonstrating gross total resection of the mass. Red arrows demonstrate removal of the previously enlarging lesion.
SNI-11-238-g003.jpg
PMC7451149_01_SNI-11-238-g003.jpg
F3
Postoperative imaging, as visualized in [Figure 3], demonstrated gross total resection (GTR) of the mass.
The histopathology obtained from the patient; (a-c) the hematoxylin and eosin staining demonstrating staghorn appearance with additional positivity for CD34 (d) and signal transducer and activator of transcription 6 (e), confirming solitary fibrous tumor/ hemangiopericytoma.
SNI-11-238-g004.jpg
PMC7451149_01_SNI-11-238-g004.jpg
F4
The patient also had transient loss of vision in the left eye which returned to preoperative baseline before discharge from the hospital. [Figure 4] demonstrates the pathology obtained from the patient; [Figure 4a-c] displays the hematoxylin and eosin staining which demonstrates a mesenchymal neoplasm with moderate cellularity and nuclear pleomorphism. Furthermore, staghorn appearance and additional strong positivity for CD34 was noted along endothelial cells with no definitive staining of tumor cells [Figure 4d] as well as strong nuclear staining for signal transducer and activator of transcription 6 (STAT6) [Figure 4e], confirming the diagnosis of SFT/HPC.